Abstract
Mitochondria are the principal site for the generation of cellular ATP by oxidative phosphorylation. F0F1-ATP synthase, a complex V of the electron transport chain, is an important constituent of mitochondria-dependent signaling pathways involved in apoptosis. In the present study, we have shown for the first time that 3,3′-diindolylmethane (DIM), a DNA topoisomerase I poison, inhibits mitochondrial F0F1-ATP synthase of Leishmania donovani and induces programmed cell death (PCD), which is a novel insight into the mechanism in protozoan parasites. DIM-induced inhibition of F0F1-ATP synthase activity causes depletion of mitochondrial ATP levels and significant stimulation of mitochondrial reactive oxygen species (ROS) production, followed by depolarization of mitochondrial membrane potential (ΔΨm). Because ΔΨm is the driving force for mitochondrial ATP synthesis, loss of ΔΨm results in depletion of cellular ATP level. The loss of ΔΨm causes the cellular ROS generation and in turn leads to the oxidative DNA lesions followed by DNA fragmentation. In contrast, loss of ΔΨm leads to release of cytochrome c into the cytosol and subsequently activates the caspase-like proteases, which lead to oligonucleosomal DNA cleavage. We have also shown that mitochondrial DNA-depleted cells are insensitive to DIM to induce PCD. Therefore, mitochondria are necessary for cytotoxicity of DIM in kinetoplastid parasites. Taken together, our study indicates for the first time that DIM-induced mitochondrial dysfunction by inhibition of F0F1-ATP synthase activity leads to PCD in Leishmania spp. parasites, which could be exploited to develop newer potential therapeutic targets.
Footnotes
-
This work was supported by the grants from Network Project NWP-38 of Council of Scientific and Industrial Research, Government of India.
-
ABBREVIATIONS: PCD, programmed cell death; ROS, reactive oxygen species; ΔΨm, mitochondrial membrane potential; DIM, 3,3′-diindolylmethane; CPT, camptothecin; ICE, interleukin-1β converting enzyme; DMSO, dimethyl sulfoxide; NAC, N-acetyl-l-cysteine; SB, sodium benzoate; BHT, butylated hydroxy toluene; MTT, 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenylterazolium bromide; PBS, phosphate-buffered saline; ELISA, enzyme-linked immunosorbent assay; PMSF, phenylmethylsulfonyl fluoride; JC-1, 5,5′6,6′-tetraethylbenzimidazolcarbocyanine iodide; H2DCFDA, 2′,7′-dichlorodihydrofluorescein diacetate; GSH, glutathione; DEVD, Asp-Glu-Val-Asp; LEHD, Leu-Glu-His-Asp; AFC, 7-amino-4-trifluoromethyl coumarin; PARP, poly(ADP-ribose) polymerase; FITC, fluorescein isothiocyanate; PI, propidium iodide; FBS, fetal bovine serum; topo, topoisomerase; ETC, electron transport chain; CCCP, carbonyl cyanide m-chloro-phenylhydrazone; mtDDC, mitochondrial DNA-depleted leishmanial cell; mtDNA, mitochondrial DNA.
-
↵ The online version of this article (available at http://molpharm.aspetjournals.org) contains supplemental material.
- Received June 30, 2008.
- Accepted August 13, 2008.
- The American Society for Pharmacology and Experimental Therapeutics
MolPharm articles become freely available 12 months after publication, and remain freely available for 5 years.Non-open access articles that fall outside this five year window are available only to institutional subscribers and current ASPET members, or through the article purchase feature at the bottom of the page.
|